Triclosan-induced alteration of gut microbiome and aggravation of asthmatic airway response in aeroallergen-sensitized mice

To the Editor,

Triclosan (2,4,4′-trichloro-2′-hydroxydiphenyl ether) is a synthetic, broad-spectrum antimicrobial agent used extensively in various healthcare products and household consumer goods such as soap, detergents, toothpastes, and other products. Triclosan (TCS) was first introduced in the 1960s for the use in clinical applications. Reports have suggested that TCS is absorbed in human skin and oral mucosa; and it has been detected in various human tissues and fluids. In addition, toxicological studies have shown that TCS exposure induces physiological perturbations in animals and in humans. Recently, a risk assessment undertaken by the US Food and Drug Administration (FDA) revealed that TCS was present in the urine samples of 75% of the US general population, and, in 2016, the FDA banned its use in soap products. Over the last 6 years, a number of studies have identified a positive correlation between the urinary TCS level and sensitization to food, aeroallergens, and perturbations in asthmatic patients. In addition, an experimental study has shown that topical application of TCS enhances allergic response in ovalbumin (OVA)-sensitized mice, suggesting that TCS might play an adjuvant role in the allergic response to environmental allergens. However, there has still been insufficient evidence to support a relationship between perturbation of the gut microbiome and allergic manifestations in relation to TCS exposure. The aim of this study was to evaluate the in vivo TCS-induced alteration of the gut microbiome and aggravation of asthmatic airway response in aeroallergen-sensitized mice.

We performed two independent experiments. In the first experiment, wild type BALB/cJ mice (n = 36) were randomly divided into 6 groups of six animals, including normal mice group (normal), Der f sensitized mice group (wild type + Der f), 5 mg/kg TCS-treated mice group (wild type + Der f + 5 mg/kg triclosan), 50 mg/kg TCS-treated mice group (wild type + Der f + 50 mg/kg triclosan), and 500 mg/kg TCS-treated mice group (wild type + Der f + 500 mg/kg triclosan). In the second experiment, knockout TLR-2 (-/-) mice (n = 12) were randomly divided into two groups of six animals that received 4 μg of Der f intratracheally 2 days per week for a total of 4 weeks. Both groups were treated either with vehicle (TLR-2 (-/-) mice + Der f group) or triclosan 500 mg/kg (TLR-2 (-/-) mice + Der f + triclosan group) through oral gavage 5 days per week for a total of 4 weeks. On the other hand, airway hyperresponsiveness (AHR) to intravenous acetylcholine (ACH) was performed as previously described, whereas bronchoconstriction was measured according to the overflow method using a bronchospasm transducer connected to the tracheal cannula. Changes in respiratory overflow volume were measured using an increasing dose of ACh. The area under the curve (AUC), calculated from the dose-response curves for ACh, was used to express the magnitude of AHR (ImageJ software, National Institutes of Health, Bethesda, Maryland, USA). On day 23, bronchoalveolar lavage (BAL) was performed and BAL fluid (BALF) was recovered for eosinophils enumeration and also IL-4 and IL-13 level measurements by ELISA. Blood samples and lung specimens were collected to measure the serum level of anti-Der f IgE and perform the histopathological examination, respectively. Furthermore, mouse fecal samples were collected to isolate microbial genomic DNA using a NucleoSpin® DNA Stool® Kit, and 16S rRNA gene sequencing was performed following procedures described by Shen et al. Data are presented as the mean ± SEM, and statistical comparisons among the treatment groups were performed with the use of one-way ANOVA test followed by the nonparametric Tukey test, whereas the abundance of bacterial genes was compared using Student’s t test (SPSS software package). Detailed methodology is provided in Supporting informations.

As results, simultaneous exposure of wild-type mice to TCS and Der f induced:

1. An increase in the production of anti-Der f IgE, IL-4, and IL-13 (Figure 1D-B-E), which resulted in the aggravation of airway hyperresponsiveness in aeroallergen-exposed wild type mice (Figure 1A), whereas these changes were not observed in non-sensitized mice;

2. Increased collagen deposition and infiltration of inflammatory cells (eosinophils) in the lungs of aeroallergen-exposed wild type mice as shown in Figure 1C.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2018 The Authors. Allergy Published by John Wiley and Sons Ltd.
3). Goblet cell hyperplasia in the lungs of sensitized wild type mice, whereas, in contrast, TLR-2 (−/−) mice did not show any allergic response after exposure to TCS (Figure 2A).

On the other hand, regarding the mouse microbial community analysis, the copy numbers of bacterial 16S rRNA gene of c_Deltaproteobacteria, c_Clostridia, and c_Erysipelotrichi in TCS-treated Der f-sensitized mice increased in a dose-dependent manner, whereas it markedly decreased in c_Bacteroidia (Figure 2B-C). Furthermore, for peripheral blood Treg cells (CD4+ CD25-high FOXP3+ T cells), no significant difference was observed among mice groups (Figure 2D).

This study showed that a simultaneous exposure to TCS and environmental aeroallergen induced an increased production of IL-4, IL-13, which are representatives Th-2 cytokines associated with allergic response, and anti-Der f IgE. Additionally, a perturbation of gut microbiome, an intense eosinophilic infiltration, and goblet cell hyperplasia, one of the prominent features of animal models of atopic asthma consecutive to repeated challenges with an allergen, were observed.

Our experiments were performed in duplicate, and the primary animal study showed high levels of the representative Th-2 cytokines, including IL-5, in the BALF of TCS and Der f-exposed animals; but the latter was not measured in the secondary experiments due to insufficient BALF samples. This constitutes a limitation for this work. Taken together, findings from this study indicate that exposure to TCS and aeroallergen exposure induces and/or aggravates AHR and inflammation and that there is a possible relationship between TCS-induced aggravation of AHR and the perturbation of gut microbiome in aeroallergen-sensitized mice. This suggests that TCS might play an adjuvant role in the induction or aggravation of allergic response in susceptible individuals.
Histopathological images of lung specimens and taxonomic profiles of microbial communities in gut microbiota. The figure shows [1] representative photomicrographs at 10 times magnification (inset) of HE (histology) (A (a-f)), PAS (mucin) (A (g-l)), MT (fibrosis) (A (m-r)) staining of mouse lung specimens obtained 23 d after the intratracheal instillation of Der f. BALB/cJ mice were randomly divided into six groups (n = 36) and treated with saline (normal group) (A (a, g, m)) or 4 μg Der f (A (b, h, n)), or Der f + triclosan (5 mg/kg (A (c, i, o)), 50 mg/kg (A (d, j, p)), 500 mg/kg (A (e, k, q)) and Der f + DEP (asthma) (A (f, l, r)). The triclosan-treated mice (A (c-e, i-k, o-q)) showed a marked increase in goblet cell hyperplasia, eosinophil infiltration, and the numbers of PAS-positive cells and collagen fibers in the lung. Black arrows indicate representative eosinophils in the infiltrate (A (c, d, e, f)), yellow arrows indicate PAS-positive cells (A (i, j, k, l)), green arrows indicate subepithelial fibrosis (A (o, p, q, r)), magnification 10x.

Abbreviations: AL, alveolus; BR, bronchiole; V, blood vessel; G, goblet cell hyperplasia; [2] the relative abundance of gut microbial species (B,C), and the proportions of Treg cells, defined as CD4^+^CD25^-^FOXP3^+^T cells (D). The copy numbers of the bacterial 16S rRNA gene of c_Deltaproteobacteria, c_Clostridia, and c_Erysipelotrichi in triclosan-treated Der f-exposed mice increased in a dose-dependent manner. In contrast, the copy number of the bacterial 16S rRNA gene of c_Bacteroidia decreased (B,C). No significant difference was observed in terms of proportions of Treg cells, defined as CD4^+^ CD25-high FOXP3^+^T cells (D).
Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study

To the Editor,
We previously showed the effectiveness and safety of omalizumab in children with severe allergic asthma.1,2 However, data on optimal treatment duration and discontinuation are limited.3 They mainly concern adults.4–7 This real-life study reports asthma outcomes comparing children maintained on omalizumab or discontinuing omalizumab after long-term treatment.

This study was conducted in 10 French pediatric pulmonology tertiary centers (Hauts de France, Normandie, Paris) and approved by the Research Ethics Committee of the French Society of Pediatrics and by the French Data Protection Authority (CNIL). Children, aged 6–18 years with severe allergic asthma and a minimum 24-month course of omalizumab, were included.8 Omalizumab indication was based on the recommendations of the French Health Drug